|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 帕博利珠单抗治疗伴脑转移NSCLC患者的一项非随机、开放Ⅱ期试验的长期随访结果和生物标志物分析显示文摘背景与目的我们开展了一项帕博利珠单抗用于伴未治疗脑转移的非小细胞肺癌(non-small cell lung cancer,NSCLC)或黑色素瘤患者的疗效和安全性的II期试验,旨在评估程序性死亡受体1(programmed cell death 1,PD-1)抑制剂在中枢神经系统(central nervous system,CNS)中的疗效。中期结果已发表,现报道对NSCLC队列的更新分析结果。方法这是一项开放性、单中心、II期试验。纳入标准:年龄≥18岁,诊断为晚期NSCLC并伴有≥1个5 mm-20 mm脑转移病灶,既往从未治疗或之前放疗后进展,无神经系统症状,不需要激素治疗且美国东部肿瘤协作组(Eastern Cooperative Oncology Group,ECOG)<2分。患者每2周接受一次帕博利珠单抗(10 mg/kg)治疗。队列1为程序性死亡配体1(programmed cell death ligand 1,PD-L1)≥1%的患者,队列2为PD-L1<1%或未评估的患者。主要终点是脑转移患者缓解比例。所有经治患者均纳入疗效与安全性终点的分析。该研究已结束入组,并于Clinicaltrials.gov登记注册,注册号为NCT02085070。结果2014年3月31日-2018年5月21日,共42例患者接受治疗。中位随访时间为8.3个月(IQR:4.5个月-26.2个月)。队列1的37例患者中11例有脑转移缓解[29.7%(95%CI:15.9%-47.0%)]。队列2未观察到缓解。治疗相关的3级-4级不良事件(adverse events,AEs)包括2例肺炎、1例全身症状、1例结肠炎、1例肾上腺皮质功能不全、1例高血糖症和1例低钾血症。6例(14%)患者发生了治疗相关的严重不良事件,包括肺炎、急性肾损伤、低钾血症和肾上腺皮质功能不全。没有观察到治疗相关死亡病例。结论帕博利珠单抗治疗PD-L1≥1%的NSCLC伴脑转移患者有效,且对所有纳入的未经治疗的脑转移患者安全。需要进一步探索免疫治疗用于NSCLC合并CNS转移。 | Sarah B GOLDBERG Kurt A SCHALPER Scott N GETTINGER Amit MAHAJAN Roy S HERBST Anne C CHANG Rogerio LILENBAUM Frederick H WILSON Sacit Bulent OMAY James B YU Lucia JILAVEANU Thuy TRAN Kira PAVLIK Elin ROWEN Heather GERRSH Annette KOMLO Richa GUPTA Hailey WYATT Matthew RIBEIRO Yuval KLUGER Geyu ZHOU Wei WEI Veronica L CHANG Harriet M KLUGER 董晓荣(翻译/校对) | 2021 | 中国肺癌杂志2021，24，9： | 34 |
| 2 | Accuracy of biometric formulae for intraocular lens power calculation in a teaching hospital显示文摘AIM: To evaluate the accuracy of three commonly used biometric formulae across different axial lengths(ALs) at one United States Veterans Affairs teaching hospital.METHODS: A retrospective chart review was conducted from November 2013 to May 2018. One eye of each patient who underwent cataract surgery with a monofocal intraocular lens(IOL) was included. The range of postoperative follow-up period was from 3 wk to 4 mo. The Holladay 2, Barrett Universal II, and Hill-Radial Basis Function(Hill-RBF) formulae were used to predict the postoperative refraction for all cataract surgeries. For each formula, we calculated the prediction errors [including mean absolute prediction error(MAE)] and the percentage of eyes within ±0.25 diopter(D) and ±0.5 D of predicted refraction. We performed subgroup analyses for short(AL<22.0 mm), medium(AL 22.0-25.0 mm), and long eyes(AL>25.0 mm).RESULTS: A total of 1131 patients were screened, and 909 met the inclusion criteria. Resident ophthalmologists were the primary surgeons in 710(78.1%) cases. We found no statistically significant difference in predictive accuracy among the three formulae over the entire AL range or in the short, medium, and long eye subgroups. Across the entire AL range, the Hill-RBF formula resulted in the lowest MAE(0.384 D) and the highest percentage of eyes with postoperative refraction within ±0.25 D(42.7%) and ±0.5 D(75.5%) of predicted. All three formulae had the highest MAEs(>0.5 D) and lowest percentage within ±0.5 D of predicted refraction(<55%) in short eyes.CONCLUSION: In cataract surgery patients at our teaching hospital, three commonly used biometric formulae demonstrate similar refractive accuracy across all ALs. Short eyes pose the greatest challenge to predicting postoperative refractive error. | Kevin S Tang Elaine M Tran Allison J Chen David R Rivera Jorge J Rivera Paul B Greenberg | 2020 | International Journal of Ophthalmology(English edition)2020，13，1： | 3 |
| 3 | Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab显示文摘AIM:To investigate the safety and efficacy of adding bevacizumab to first-line chemotherapy in metastatic colorectal cancer patients with peritoneal disease.METHODS:We compared rates of gastrointestinal perforation in patients with metastatic colorectal cancer and peritoneal disease receiving first-line chemotherapy with and without bevacizumab in three distinct cohorts:(1) the AGITG MAX trial(Phase Ⅲ randomised clinical trial comparing capecitabine vs capecitabine and bevacizumab vs capecitabine,bevacizumab and mitomycin C);(2) the prospective Treatment of Recurrent and Advanced Colorectal Cancer(TRACC) registry(any first-line regimen ± bevacizumab);and(3) two cancer centres in New South Wales,Australia [Macarthur Cancer Therapy Centre and Liverpool Cancer Therapy Centre(NSWCC) from January 2005 to Decenber 2012,(any first-line regimen ± bevacizumab).For the AGITG MAX trial capecitabine was compared to the other two arms(capecitabine/bevacizumab and capecitabine/bevacizumab/mitomycin C).In the AGITG MAX trial and the TRACC registry rates of gastrointestinal perforation were also collected in patients who did not have peritoneal metastases.Secondary endpoints included progression-free survival,chemotherapy duration,and overall survival.Time-toevent outcomes were estimated using the Kaplan-Meier method and compared using the log-rank test.RESULTS:Eighty-four MAX,179 TRACC and 69 NSWCC patients had peritoneal disease.There were no gastrointestinal perforations recorded in either the MAX subgroup or the NSWCC cohorts.Of the patients without peritoneal disease in the MAX trial,4/300(1.3%) in the bevacizumab arms had gastrointestinal perforations compared to 1/123(0.8%) in the capecitabine alone arm.In the TRACC registry 3/126(2.4%) patients who had received bevacizumab had a gastrointestinal perforation compared to 1/53(1.9%) in the chemotherapy alone arm.In a further analysis of patients without peritoneal metastases in the TRACC registry,the rate of gastrointestinal perforations was 9/369(2.4%) in the chemotherapy/bevacizumab group and 5/177(2.8%) in the chemotherapy alone group.The addition of bevacizumab to chemotherapy was associated with improved progression-free survival in all three cohorts:MAX 6.9 m vs 4.9 m,HR = 0.64(95%CI:0.42-1.02);P = 0.063;TRACC 9.1 m vs 5.5 m,HR = 0.61(95%CI:0.37-0.86);P = 0.009;NSWCC 8.7 m vs 6.8 m,HR = 0.75(95%CI:0.43-1.32);P = 0.32.Chemotherapy duration was similar across the groups.CONCLUSION:Patients with peritoneal disease do not appear to have an increased risk of gastrointestinal perforations when receiving first-line therapy with bevacizumab compared to systemic therapy alone. | Aflah Roohullah Hui-Li Wong Katrin M Sjoquist Peter Gibbs Kathryn Field Ben Tran Jeremy Shapiro Joe Mckendrick Desmond Yip Louise Nott Val Gebski Weng Ng Wei Chua Timothy Price Niall Tebbutt Lorraine Chantrill | 2015 | World Journal of Gastroenterology2015，21，17： | 3 |
| 4 | p53 protein overexpression in low grade dysplasia (LGD) in barrett’s esophagus: Immunohistochemical marker predictive of progression显示文摘 | Allan P Weston Sushanta K Banerjee Prateek Sharma Trang M Tran Robert Richards Rachel Cherian | 2001 | The American Journal of Gastroenterology2001，，5： | 2 |
| 5 | Effect of cortical cooling on interictal epileptiform activities显示文摘 | Ablah E Tran M P Isaac M | 2009 | Seizure2009，18，1： | 1 |
| 6 | Prevalence of antibody against hepatitis E virus in variousspecies of non-human primates:evidence of widespread infection in Japanese monkeys(Macaca fuscata)显示文摘 | Hirano M Ding X Tran H T | 2003 | Jpn J Infect2003，56，： | 1 |
| 7 | R-Spondin family members regulate the Wnt pathway by a common mechanism显示文摘 | Kim K A Wagle M Tran K Zhan X Dixon M A Liu S | 2008 | Mol Biol Cell2008，19，： | 1 |
| 8 | Direct flower neoformation from superficial tissue of small explants of Nicotiana tabacun显示文摘 | TRAN THANH VAN M | 1993 | planta1993，115，： | 1 |
| 9 | Distribution andgenetic diversity of lactic acid bacteria from traditional fermentedsausage显示文摘 | TRAN KTM MAY B E SMOOKER P M et ai | 2011 | Food Research International2011，44，1： | 1 |
| 10 | A randomized controlled trial of sequentially bilateral prefrontal cortex repetitive transcranial magnetic stimulation in the treatment of negative symptoms in schizophrenia显示文摘 | Barr M S Farzan F Tran L C | 2012 | Brain Stimul2012，5，3： | 1 |
| 11 | Robust analysis of the yeast proteome under 50 kDa by molecular-massbased fractionation and top-down mass spectrometry显示文摘 | Kellie J F Catherman A D Durbin K R Tran J C Tipton J D Norris J L Witkowski C E 2nd Thomas P M Kelleher N L | | 0，，01： | 1 |
| 12 | Phenamide, a fungicidal metabolite from Streptomyces albospinus A19301 taxonomy, fermentation, isolation, physico-chemical and biological properties 显示文摘 | Makkar N S Nickson T E Tran M | 1995 | The Journal of Antibiotics1995，48，5： | 1 |
| 13 | Identification of galactose-a-1, 3-galactose in the gastrointestinal tract of the tick Ixodes ricinus; possible relationship with red meat allergy 显示文摘 | Hamsten C Starkhammar M Tran TA | 2013 | Allergy2013，68，： | 1 |
| 14 | Determination of spread of injectate after ultrasound-guided transversus abdominis plane block:a cadaveric study显示文摘 | Tran T M Ivanusic J J Hebbard P | 2009 | Br J Anaesth2009，102，1： | 1 |
| 15 | Deep venous thrombosis in patients with hematological malignancies after peripherally inserted central venous catheters显示文摘 | Tran H Arellano M Chamsuddin A | 2010 | Leuk Lymphoma2010，51，8： | 1 |
| 16 | Two-phase pressure drop of refrigerants during flow boiling in small channels:an experimental investigation and correlation development显示文摘 | Tran T N Chyu M C Wambsganss M W | 2000 | Int J Multiphase Flow2000，26，： | 1 |
| 17 | Isolation and functional analysis of Arabidopsis stress-inducible NAC transcription factors that bind to a drought responsive Cis-element in the EARLY RESPONSIVE TO DEHYDRATION STRESS promoter显示文摘 | TRAN L NAKASHIMA K SAKUMA Y SIMPSON S D FUJITA Y MARUYAMA K FUJITA M SEKI M SHINOZAKI K YAMAGUCHI-SHINOZAKI K | 2004 | The Plant Cell2004，16，9： | 1 |
| 18 | Dexmedetomidine infusion for analgesia and prevention Of emergence agitation in children with obstructive sleep apnea syndrome undergoing tonsillectomy and adenoidectomy显示文摘 | Patel A Davidson M Tran MC | 2010 | Anesth Analg2010，111，4： | 1 |
| 19 | Near-Infrared Spectroscopic Investigation of Inclusion Complexes Between Cyclodextrinsand Aromatic Compounds 显示文摘 | Politi M J’Tran C D Gao G H | 1995 | J Phys Chem1995，99，14： | 1 |
| 20 | Review of piezodialysis- salt removal with charge mosaic membranes显示文摘 | Bolto B Hoang M Tran T | 2010 | Desali- nation2010，254，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员